Pulmonx (LUNG) Cash & Current Investments (2019 - 2025)

Pulmonx (LUNG) has reported Cash & Current Investments for 7 consecutive years, with $69.8 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Cash & Current Investments fell 31.27% year-over-year to $69.8 million in Q4 2025; TTM through Dec 2025 was $69.8 million, a 31.27% decrease from a year earlier, with the FY2025 full-year figure at $69.8 million, down 31.27% from the prior year.
• Cash & Current Investments was $69.8 million for Q4 2025 at Pulmonx, down from $76.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $219.1 million in Q1 2021 and troughed at $69.8 million in Q4 2025.
• A 5-year average of $136.0 million and a median of $126.1 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 1248.85% in 2021 and sank 31.27% in 2025, its largest moves.
• Over 5 years, Cash & Current Investments stood at $180.0 million in 2021, then retreated by 21.61% to $141.1 million in 2022, then declined by 17.03% to $117.1 million in 2023, then decreased by 13.34% to $101.5 million in 2024, then slumped by 31.27% to $69.8 million in 2025.
• The last three Cash & Current Investments figures came in at $69.8 million (Q4 2025), $76.5 million (Q3 2025), and $84.2 million (Q2 2025), per Business Quant data.